Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02617628 · ClinicalTrials.gov registry record · Phase 2
Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 146
- Enrollment target
NCT02617628: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT02617628 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 146 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02617628, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 146 participants
- Enrollment target
Study Summary
This study is a collaboration between the University of Pennsylvania, the Philadelphia Prison System, and the North East Treatment Center (NETSteps). It purpose is to study the impact of an injectable opiate addiction medication (extended release naltrexone) given before reentry into the community that might help to improve reconnection to healthcare and other support systems, and possibly help reduce recidivism.
Interventions
- DRUG extended release naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2016-01-01 |
| Est. Completion | 2018-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02617628
The ClinicalTrials.gov registry entry for NCT02617628 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which extended release naltrexone is the first listed.
NCT02617628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02617628 about?
NCT02617628 is a clinical study titled "Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone". This study is a collaboration between the University of Pennsylvania, the Philadelphia Prison System, and the North East Treatment Center (NETSteps). It purpose is to study the impact of an injectable opiate addiction medication (extended release naltrexone) given before reentry into the community t...
What is the current status of trial NCT02617628?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 146 participants. The study started on 2016-01-01. Estimated completion is 2018-12-31.
What interventions are being tested in trial NCT02617628?
The interventions under investigation include: extended release naltrexone (DRUG).
Who is sponsoring clinical trial NCT02617628?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.